HC50 Hemolytic Activity Testing: Determination of the 50% Hemolysis Rate

The HC50 hemolytic activity test determines the concentration of a test substance that lyses 50% of a red blood cell population, providing a quantitative measure of membrane-damaging potential and blood compatibility. As an in vitro assay aligned with frameworks such as ISO 10993-4, ASTM F756, and GB/T 16886.4, it is widely used by accredited third-party laboratories for the safety evaluation of surfactants, cosmetics, disinfectants, pharmaceuticals, and medical devices. This article explains the principle, methodology, sample types, applications, and common questions related to the 50% hemolysis rate test.

Technical Overview

Hemolysis refers to the rupture of erythrocyte (red blood cell) membranes and the subsequent release of hemoglobin into the surrounding medium. The HC50 test, also known as the 50% hemolysis rate or median hemolytic concentration assay, quantifies the concentration of a test substance required to lyse 50% of a standardized red blood cell suspension under controlled in vitro conditions. The released hemoglobin is measured spectrophotometrically, typically at an absorbance wavelength of 540–545 nm, and a dose–response curve is constructed to derive the HC50 value.

The interpretation of the result is inversely proportional to potency: a lower HC50 indicates stronger hemolytic activity and greater potential to damage biological membranes, whereas a higher HC50 indicates milder membrane interaction. Because erythrocyte membrane disruption correlates reasonably well with eye and mucous membrane irritation for surfactant-type materials, the HC50 assay has historically served as an animal-free screening method, particularly in cosmetic and personal care safety evaluation. For blood-contacting medical devices and materials, hemolytic activity testing supports biocompatibility assessment under ISO 10993-4, ASTM F756, and the Chinese national standard GB/T 16886.4.

Testing Samples

Surfactants and Detergent Ingredients

Anionic, nonionic, cationic, and amphoteric surfactants are among the most frequently tested sample categories. The HC50 value is used to rank the mildness of surfactants and to guide the selection of raw materials for cleansing products.

Cosmetics and Personal Care Products

Finished formulations such as shampoos, facial cleansers, body washes, hand soaps, and oral care products, as well as individual cosmetic ingredients and botanical extracts, can be evaluated for hemolytic activity as part of irritation screening programs.

Disinfectants and Antiseptics

Surface disinfectants, skin antiseptics, and antimicrobial formulations often contain membrane-active agents whose hemolytic potential should be characterized to assess tissue compatibility.

Pharmaceutical Products and Excipients

Intravenous injectables, infusion solutions, excipients, and formulation components are tested to ensure they do not cause unacceptable erythrocyte damage at clinically relevant concentrations.

Medical Devices and Biomaterials

Extracts of blood-contacting devices such as catheters, infusion sets, dialysis components, stents, and tubing are evaluated for hemolytic activity in support of biological evaluation per ISO 10993-4, ASTM F756, and GB/T 14233.2 for infusion and transfusion equipment.

Chemicals, Nanomaterials, and Research Compounds

Industrial chemicals, nanomaterials, biomaterials, antimicrobial peptides, saponins, and other membrane-active compounds are tested in research and preclinical contexts to characterize their interaction with cellular membranes.

Testing Items

Typical deliverables of an HC50 hemolytic activity study include:

• HC50 value: the concentration of the test substance producing 50% hemolysis, reported with confidence intervals where applicable.
• Complete dose–response curve: hemolysis percentage plotted across a geometric dilution series of the test substance.
• Hemolysis rate at specified concentrations: single-point hemolysis percentages at client-defined or standard-defined concentrations.
• Comparative hemolytic activity: benchmarking of multiple samples or formulations under identical test conditions.
• Control validation data: confirmation that positive and negative controls meet predefined acceptance criteria.

Testing Methods

The HC50 assay is performed through a controlled incubation of erythrocytes with serial dilutions of the test article, followed by spectrophotometric quantification of released hemoglobin. A representative workflow is described below.

Preparation of the Erythrocyte Suspension

Fresh anticoagulated blood (commonly rabbit, human, or sheep blood, depending on the protocol and regulatory context) is collected using a suitable anticoagulant. The erythrocytes are washed repeatedly with isotonic phosphate-buffered saline (PBS) or physiological saline via centrifugation until the supernatant is visually clear, and the packed cells are then diluted to a standardized red blood cell suspension.

Preparation of Test Dilutions

The test substance is diluted serially in isotonic buffer to generate a geometric concentration series, typically spanning the range from negligible to complete hemolysis. For medical devices, extraction is performed in a defined medium under conditions consistent with ISO 10993-12 or the applicable product standard.

Incubation

Equal volumes of the erythrocyte suspension and each test dilution are mixed and incubated, commonly at 37 °C ± 1 °C for approximately 30 to 60 minutes with gentle mixing, ensuring consistent contact between cells and test article.

Controls

• Positive control: distilled water or a detergent solution such as Triton X-100, which induces complete (100%) hemolysis.
• Negative control: isotonic PBS or saline, which should produce negligible hemolysis.
• Sample blanks: test article dilutions without red blood cells, used to correct for intrinsic color or absorbance of colored or turbid samples.

Measurement and Calculation

Following incubation, samples are centrifuged to pellet intact erythrocytes, and the absorbance of the supernatant is measured at 540–545 nm. The hemolysis percentage for each concentration is calculated as: Hemolysis (%) = (A_sample − A_negative) / (A_positive − A_negative) × 100. The concentration–response data are then fitted (for example, by a four-parameter logistic or probit model) to determine the concentration corresponding to 50% hemolysis, which is reported as the HC50.

Validity Criteria

A run is considered valid when the negative control remains within the specified low-hemolysis limit, the positive control achieves near-complete hemolysis, and replicate variability falls within predefined acceptance limits. Studies should be conducted under quality systems such as GLP or ISO/IEC 17025 accreditation as required by the client or regulator.

Applications

The HC50 hemolytic activity test supports product safety evaluation across multiple industries:

• Cosmetic safety screening: used as an in vitro indicator of eye and mucous membrane irritation potential for surfactant-based products, supporting animal-free safety strategies in markets where animal testing restrictions apply.
• Surfactant mildness ranking: enables suppliers and formulators to compare the membrane harshness of raw materials and optimize cleansing formulations.
• Medical device biocompatibility: provides hemocompatibility data required for blood-contacting devices under ISO 10993-4, ASTM F756, GB/T 16886.4, and related national standards.
• Pharmaceutical development: confirms that parenteral formulations and excipients do not induce unacceptable hemolysis at intended exposure levels.
• Chemical hazard characterization: contributes to understanding membrane-damaging potential in classification and labeling workflows.
• Research applications: supports studies of membrane-active compounds, including antimicrobial peptides, saponins, natural extracts, and engineered nanomaterials.

FAQ

What does HC50 mean?

HC50 is the median hemolytic concentration: the concentration of a test substance that causes 50% hemolysis of a red blood cell suspension under defined experimental conditions. It is derived from a full dose–response curve rather than a single measurement.

Is a lower HC50 value better or worse?

A lower HC50 indicates stronger hemolytic activity, meaning the substance damages erythrocyte membranes at lower concentrations and may present a higher irritation or biocompatibility concern. A higher HC50 indicates milder membrane interaction.

How does the HC50 test differ from a simple hemolysis ratio test?

A hemolysis ratio test measures the percentage of hemolysis at one fixed concentration or with one extract, while the HC50 test evaluates a complete concentration series and identifies the concentration that produces 50% hemolysis. The HC50 result is therefore a potency metric that enables quantitative comparison between substances.

Which blood source is used?

Rabbit blood is commonly used in historical cosmetic irritation screening protocols, while human and sheep blood are also employed depending on the applicable standard and laboratory practice. Because red blood cell sensitivity varies by species, comparisons between studies should always confirm that the same blood source and protocol were used.

Which standards govern hemolytic activity testing?

Relevant frameworks include ISO 10993-4 and GB/T 16886.4 for the biological evaluation of medical devices interacting with blood, ASTM F756 for the assessment of hemolytic properties of materials, and GB/T 14233.2 for infusion, transfusion, and injection equipment. Accredited third-party laboratories select the appropriate protocol based on product type and target market.

Can colored or turbid samples be tested?

Yes. Sample blanks containing the test article without red blood cells are used to subtract intrinsic absorbance. Strongly colored, opaque, or precipitating samples may require method adaptation, and the laboratory should be consulted during study design.

How much sample is needed and how long does testing take?

Sample requirements are generally modest, often on the order of grams or milliliters depending on the dilution range. Typical turnaround for a standard HC50 study at an accredited third-party laboratory is one to two weeks, subject to sample handling and protocol requirements.